Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Holding(s) in Company

31 Mar 2008 14:04

CareCapital Group plc31 March 2008 CareCapital Group plc TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached: CareCapital Group plc 2. Reason for the notification: An acquisition or disposal of voting rights: 3. Full name of person(s) subject to the notification obligation: HSBC Global Custody Nominee (UK) ltd 4. Full name of shareholder(s): New Solera Holdings Limited BVI 5. Date of the transaction (and date on which the threshold is crossed orreached if different): 26 March 2008 6. Date on which issuer notified: 27 March 2008 7. Threshold(s) that is/are crossed or reached: Above 7% 8. Notified details: ................. A: Voting rights attached to shares Class/type of shares if possible Situation previous to theusing the ISIN CODE Triggering transaction (vi) Number of Number of voting shares Rights (viii) GB00B16JQ761 5,083,336 5,083,336 Resulting situation after the triggering transaction (vii) Class/type of shares Number of shares Number of voting rights % of voting rightsif possible using (ix)the ISIN CODE Direct Direct (x) Indirect (xi) Direct Indirect 5,583,336 5,583,336 7.27% B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Date Exercise/Conversion Number of voting % of votingfinancial (xiii) Period/ Date (xiv) rights that may be rightsinstrument acquired if the instrument is exercised/ converted Total (A+B)Number of voting % of votingrights rights 5,583,336 7.27% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable (xv): ................. Proxy Voting: 10. Name of the proxy holder: ................. 11. Number of voting rights proxy holder will cease to hold: ................. 12. Date on which proxy holder will cease to hold voting rights: ................. 13. Additional information: ................. 14. Contact name: Beat Bass, HSBC Guyerzeller Bank AG 15. Contact telephone number: 0041 58 206 77 41 Annex to Notification Of Major Interests In Shares (xvi) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): ................. Contact address (registered office for legal entities): ................. Phone number: ................. Other useful information (at least legal representative for legal persons): ................. B: Identity of the notifier, if applicable (xvii) Full name: HSBC Guyerzeller Bank AG, Beat Bass Contact address: Genferstrasse 8, 8027 Zurich, Switzerland Phone number: 0041 58 206 77 41 Other useful information: ................. C: Additional information : ................. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th May 20247:00 amRNSCancellation - Advanced Oncotherapy Plc
3rd May 20248:54 amRNSFurther update on financing discussions
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.